Cited by 127Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and TreatmentsChromatin Remodeling and Cancer

The DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index, and 1 are not checked yet.

Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group

Open access

Roberts, Ryan D., Lizardo, Michael M., Reed, Damon R., Hingorani, Pooja, Glover, Jason, Allen‐Rhoades, Wendy, Fan, Timothy, Khanna, Chand, Sweet‐Cordero, E. Alejandro, Cash, Thomas, Bishop, Michael W., Hegde, Meenakshi, Sertil, Aparna R., Koelsche, Christian, Mirabello, Lisa, Malkin, David, Sorensen, Poul H., Meltzer, Paul S., Janeway, Katherine A., Gorlick, Richard, Crompton, Brian D.·2019·Cancer

DOI 10.1002/cncr.32351PMC PMC6948723

Open this paper in CoChat — free account

Abstract

Patients who are diagnosed with osteosarcoma (OS) today receive the same therapy that patients have received over the last 4 decades. Extensive efforts to identify more effective or less toxic regimens have proved disappointing. As we enter a postgenomic era in which we now recognize OS not as a cancer of mutations but as one defined by p53 loss, chromosomal complexity, copy number alteration, and profound heterogeneity, emerging threads of discovery leave many hopeful that an improving understanding of biology will drive discoveries that improve clinical care. Under the organization of the Bone Tumor Biology Committee of the Children's Oncology Group, a team of clinicians and scientists sought to define the state of the science and to identify questions that, if answered, have the greatest potential to drive fundamental clinical advances. Having discussed these questions in a series of meetings, each led by invited experts, we distilled these conversations into a series of seven Provocative Questions. These include questions about the molecular events that trigger oncogenesis, the genomic and epigenomic drivers of disease, the biology of lung metastasis, research models that best predict clinical outcomes, and processes for translating findings into clinical trials. Here, we briefly present each Provocative Question, review the current scientific evidence, note the immediate opportunities, and speculate on the impact that answered questions might have on the field. We do so with an intent to provide a framework around which investigators can build programs and collaborations to tackle the hardest problems and to establish research priorities for those developing policies and providing funding.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/cncr.32351

Cites

93 of 94 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
The landscape of genomic alterations across childhood cancers
ICGC PedBrain-Seq Project, Gröbner, S. N., ICGC MMML-Seq Project, Worst, B. C., Weischenfeldt, J., Buchhalter, I., Kleinheinz, K., Rudneva, V. A., Johann, P. D., Balasubramanian, G. P., et al. (2018) · Nature · doi:10.1038/nature25480 · Cited by 1,572
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452 · cited 1×
“study, only 1 of the 22 patients with OS had an objective response to single agent pembrolizumab.(81) In the pediatric trial of nivolumab alone or in combination with ip-”
BackgroundSelf-citation
Oxidative stress inhibits distant metastasis by human melanoma cells
Piskounova, E., Agathocleous, M., Murphy, M. M., Hu, Z., Huddlestun, S. E., Zhao, Z., Leitch, A. M., Johnson, T. M., DeBerardinis, R. J., & Morrison, S. J. (2015) · Nature · doi:10.1038/nature15726 · Cited by 1,269
Metastasis: Quantitative Analysis of Distribution and Fate of Tumor Emboli Labeled With 125I-5-Iodo-2′ -deoxyuridine 2 3
Fidler, I. J. (1970) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/45.4.773 · Cited by 1,025
Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours
Ma, X., Liu, Y., Liu, Y., Alexandrov, L. B., Edmonson, M. N., Gawad, C., Zhou, X., Li, Y., Rusch, M. C., Easton, J., et al. (2018) · Nature · doi:10.1038/nature25795 · Cited by 901
Self-citation
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 900
Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency
Bouffet, E., Larouche, V., Campbell, B. B., Merico, D., de Borja, R., Aronson, M., Durno, C., Krueger, J., Cabric, V., Ramaswamy, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6552 · Cited by 857
Self-citation
Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers
Bougeard, G., Renaux-Petel, M., Flaman, J.-M., Charbonnier, C., Fermey, P., Belotti, M., Gauthier-Villars, M., Stoppa-Lyonnet, D., Consolino, E., Brugières, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5728 · Cited by 760
Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
Chen, X., Bahrami, A., Pappo, A., Easton, J., Dalton, J., Hedlund, E., Ellison, D., Shurtleff, S., Wu, G., Wei, L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.003 · Cited by 752

Flagged first, then by citations

Show all 92 references

Sorted by citations

Items 101–127 of 127

Synthesis and Antitumor Activity of a GSH Inert Bisphosphonate Platinum (II) Complex
Ma, L., Liu, H., Ju, Y., Chen, K., Yang, Y., Zhou, Z., Zhang, Z., & Cai, Z. (2022) · Journal of Chemistry · doi:10.1155/2022/3137142
PLAC8 facilitates osteosarcoma growth and metastasis by upregulating CXCL5 expression via miR-363-3pPreprint
Huang, X., Zhang, Y., Zhang, Y.-T. Y., Liu, Y., Han, X., Zhang, C., Wei, X., Xu, Y., Zhang, J., Feng, J., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2617436/v1
Research Progress of TP53 Gene Abnormality in Osteosarcoma
陈, 杨. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.133529
Data from Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach
Schott, C. R., Koehne, A. L., Sayles, L. C., Young, E. P., Luck, C., Yu, K., Lee, A. G., Breese, M. R., Leung, S. G., Xu, H., et al. (2024) · doi:10.1158/1078-0432.c.7077821.v1
Data from Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach
Schott, C. R., Koehne, A. L., Sayles, L. C., Young, E. P., Luck, C., Yu, K., Lee, A. G., Breese, M. R., Leung, S. G., Xu, H., et al. (2024) · doi:10.1158/1078-0432.c.7077821
Comparative responses to demethylating therapy in animal models of osteosarcomaPreprint
Huang, S., Ren, L., Beck, J. A., Patkar, S., Osuna, M. Á. L., Cherukuri, A., Mazcko, C. N., Krum, S. A., & LeBlanc, A. K. (2024) · Research Square · doi:10.21203/rs.3.rs-4451060/v1
Interrupting ELMSAN1 repression of nuclear acetyl-CoA production therapeutically reprograms cancer cellsPreprint
Zhao, T., He, L., Wong, L. P., Mei, S., Xia, J., Xu, Y., Vranken, J. G. V., Mazzola, M. C., Chen, L., Rhee, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.25.650293
Prognosis prediction using autophagy gene expression in osteosarcomaPreprint
Liu, Q., Zhou, C., Xu, K., Zhu, Q., Lu, J., Zhang, C., Xie, W., Fang, G., Chen, X. F. C., Tian, D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.05.685081
Additional file 11 of Nectin-4 promotes osteosarcoma progression and metastasis through activating PI3K/AKT/NF-κB signaling by down-regulation of miR-520c-3p
Liu, Y., Li, G., Zhang, Y., Li, L., Zhang, Y., Huang, X., Wei, X., Zhou, P., Liu, M., zhao, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20479583
Additional file 7 of Nectin-4 promotes osteosarcoma progression and metastasis through activating PI3K/AKT/NF-κB signaling by down-regulation of miR-520c-3p
Liu, Y., Li, G., Zhang, Y., Li, L., Zhang, Y., Huang, X., Wei, X., Zhou, P., Liu, M., zhao, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20479610
Additional file 6 of Nectin-4 promotes osteosarcoma progression and metastasis through activating PI3K/AKT/NF-κB signaling by down-regulation of miR-520c-3p
Liu, Y., Li, G., Zhang, Y., Li, L., Zhang, Y., Huang, X., Wei, X., Zhou, P., Liu, M., zhao, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20479604
Additional file 2 of Nectin-4 promotes osteosarcoma progression and metastasis through activating PI3K/AKT/NF-κB signaling by down-regulation of miR-520c-3p
Liu, Y., Li, G., Zhang, Y., Li, L., Zhang, Y., Huang, X., Wei, X., Zhou, P., Liu, M., zhao, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20479589
Additional file 4 of Nectin-4 promotes osteosarcoma progression and metastasis through activating PI3K/AKT/NF-κB signaling by down-regulation of miR-520c-3p
Liu, Y., Li, G., Zhang, Y., Li, L., Zhang, Y., Huang, X., Wei, X., Zhou, P., Liu, M., zhao, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20479595
Additional file 1 of Nectin-4 promotes osteosarcoma progression and metastasis through activating PI3K/AKT/NF-κB signaling by down-regulation of miR-520c-3p
Liu, Y., Li, G., Zhang, Y., Li, L., Zhang, Y., Huang, X., Wei, X., Zhou, P., Liu, M., zhao, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20479586
Additional file 9 of Nectin-4 promotes osteosarcoma progression and metastasis through activating PI3K/AKT/NF-κB signaling by down-regulation of miR-520c-3p
Liu, Y., Li, G., Zhang, Y., Li, L., Zhang, Y., Huang, X., Wei, X., Zhou, P., Liu, M., zhao, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20479616
Additional file 3 of Nectin-4 promotes osteosarcoma progression and metastasis through activating PI3K/AKT/NF-κB signaling by down-regulation of miR-520c-3p
Liu, Y., Li, G., Zhang, Y., Li, L., Zhang, Y., Huang, X., Wei, X., Zhou, P., Liu, M., zhao, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20479592
Additional file 1 of Bone-targeting exosome nanoparticles activate Keap1 / Nrf2 / GPX4 signaling pathway to induce ferroptosis in osteosarcoma cells
Chen, W., Li, Z., Yu, N., Zhang, L., Li, H., Chen, Y., Gong, F., Lin, W., He, X., Wang, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24223762
Additional file 5 of Nectin-4 promotes osteosarcoma progression and metastasis through activating PI3K/AKT/NF-κB signaling by down-regulation of miR-520c-3p
Liu, Y., Li, G., Zhang, Y., Li, L., Zhang, Y., Huang, X., Wei, X., Zhou, P., Liu, M., zhao, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20479601
Additional file 10 of Nectin-4 promotes osteosarcoma progression and metastasis through activating PI3K/AKT/NF-κB signaling by down-regulation of miR-520c-3p
Liu, Y., Li, G., Zhang, Y., Li, L., Zhang, Y., Huang, X., Wei, X., Zhou, P., Liu, M., zhao, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20479580
Additional file 8 of Nectin-4 promotes osteosarcoma progression and metastasis through activating PI3K/AKT/NF-κB signaling by down-regulation of miR-520c-3p
Liu, Y., Li, G., Zhang, Y., Li, L., Zhang, Y., Huang, X., Wei, X., Zhou, P., Liu, M., zhao, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20479613
Epigenetic patterns and methylation-based models for robust outcome prediction in osteosarcomaPreprint
Bowers, J. J., Ramavenkat, N., Lietz, C. E., Hugaboom, M., Madupur, A., Choy, E., Cote, G. M., Lee, H., Aryee, M. J., & Spentzos, D. (2025) · medRxiv · doi:10.1101/2025.11.19.25340108
Prognostic Impact of CD206 + M2 ‐Like Macrophages in Canine Appendicular Osteosarcoma
Chamel, G., Belluco, S., Barrett, L. E., Floch, F., Sayag, D., Lanore, D., Piccirillo, E., Denoeux, P., Chavalle, T., Lajoinie, M., et al. (2025) · Veterinary and Comparative Oncology · doi:10.1111/vco.70039
Osteosarcoma
McAloney, C. A., Fan, T. M., & Roberts, R. D. (2026) · Springer eBooks · doi:10.1007/978-3-032-04454-9_9
Self-citation
A machine learning-driven prognostic model based on peripheral blood lymphocyte subsets in osteosarcoma
Li, L., Liu, J., Pang, S., Zhao, Y., Wang, Y. F., Wen, J., Liu, Y., Zhang, Y., Zhang, Y., Li, J., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1733518
Genomic landscape and tumor immune microenvironment of osteosarcoma: Bridging mechanistic insights to precision therapeutics
Yang, C., Yu, Y., Wang, Y., Cai, Z., Zhao, Y., Ma, H., Xu, J., Zhu, H., Ren, T., Tang, X., et al. (2026) · Bone Reports · doi:10.1016/j.bonr.2026.101930 · Cited by 1
Spatially coordinated RTK-ERK signaling dynamics shape osteosarcoma single-cell drug response in the lung microenvironmentPreprint
Makkawi, R., Halsey, C. M. R., Murthy, V., Manalo, E. C., Cros, H., Yi, X., Cartier, J. M., Chang, M., Flory, M. R., Guptell, K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.30.755770
Self-citation
Research priority setting in childhood cancer: An integrative review
Silva, G. D., Robertson, E. G., Bowers, A. P., Cummings, J., Rolfe, M. L., Elvidge, N., & Bradford, N. (2026) · Journal of Child Health Care · doi:10.1177/13674935261500850

Authors: Roberts, R. D., Lizardo, M. M., Reed, D. R., Hingorani, P., Glover, J., Allen‐Rhoades, W., Fan, T., Khanna, C., Sweet‐Cordero, E. A., Cash, T., Bishop, M. W., Hegde, M., Sertil, A. R., Koelsche, C., Mirabello, L., Malkin, D., Sorensen, P. H., Meltzer, P. S., Janeway, K. A., Gorlick, R., & Crompton, B. D.
Affiliations: Nationwide Children's Hospital (US)
BC Cancer Agency (CA)
Moffitt Cancer Center (US)
Phoenix Children's Hospital (US)
Randall Children's Hospital at Legacy Emanuel (US)
Baylor College of Medicine (US)
University of Illinois Urbana-Champaign (US)
Ethos Vet Health Woburn Massachusetts
Division of Hematology and Oncology, Department of Pediatrics University of California San Francisco San Francisco California
Emory University (US)
St. Jude Children's Research Hospital (US)
University of Arizona (US)
Heidelberg University (DE)
National Institutes of Health (US)
University of Toronto (CA)
Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
The University of Texas MD Anderson Cancer Center (US)
Broad Institute (US)
Corresponding author: Crompton, Brian D.
ORCID: Roberts, Ryan D.
Lizardo, Michael M.
Reed, Damon R.
Hingorani, Pooja
Glover, Jason
Allen‐Rhoades, Wendy
Fan, Timothy
Bishop, Michael W.
Hegde, Meenakshi
Koelsche, Christian
Mirabello, Lisa
Malkin, David
Sorensen, Poul H.
Meltzer, Paul S.
Janeway, Katherine A.
Gorlick, Richard
Crompton, Brian D.
Venue: Cancer
Publisher: Wiley
Published: 2019-07-29
Volume: 125
Issue: 20
Pages: 3514-3525
ISSN: 0008-543X (ISSN-L)
1097-0142
DOI: 10.1002/cncr.32351
PMC: PMC6948723
OpenAlex: W2966831493
Cited by: 127
References: 92
Citations by year: 2026: 7 · 2025: 13 · 2024: 15 · 2023: 18 · 2022: 29 · 2021: 24 · 2020: 19 · 2019: 2
FWCI: 3.12
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Cancer (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (U10CA180886, K08CA188073, K08CA201638)
Topics: Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: osteosarcoma, p53 deficiency, copy number alterations, tumor heterogeneity, carcinogenesis, epigenomics, lung metastasis, preclinical models, translational research, research priorities, Children's Oncology Group
MeSH terms: Child, Humans, Mutation, Osteosarcoma, Tumor Suppressor Protein p53, Genomics, Proteomics, Translational Research, Biomedical, Epigenomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks